CG Oncology Announces Q4 2025 Earnings on Friday

Biopharmaceutical company CG Oncology (CGON) to report quarterly results ahead of market open.

Mar. 20, 2026 at 5:03am

Got story updates? Submit your updates here. ›

CG Oncology (NASDAQ:CGON), a clinical-stage biopharmaceutical company focused on antibody-based immunotherapies for solid tumor cancers, is expected to announce its Q4 2025 earnings results before the market opens on Friday, March 27, 2026.

Why it matters

As a promising biotech company in the oncology space, CG Oncology's quarterly earnings report will provide investors with key updates on the progress of its pipeline of novel cancer treatments currently in clinical trials.

The details

Analysts expect CG Oncology to report a loss of $0.61 per share for the quarter. In its previous Q4 2025 report, the company posted a loss of $0.51 per share on $2.32 million in revenue. CG Oncology's stock has seen significant gains over the past year, rising from $14.80 to a 52-week high of $69.35.

  • CG Oncology will announce its Q4 2025 earnings before the market opens on Friday, March 27, 2026.
  • The company reported Q4 2025 results on Friday, February 27, 2026.

The players

CG Oncology, Inc.

A clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers.

Got photos? Submit your photos here. ›

The takeaway

Investors will be closely watching CG Oncology's Q4 2025 earnings report for updates on the company's pipeline progress and any potential catalysts that could drive the stock price higher in the coming year.